Vaxart Gets $12.5M For Oral Vaccines
San Francisco-based Vaxart, a developer of oral vaccines, said today that it has raised $12.5M in a Series B funding round. The round was led by Care Capital. As part of the funding, Richard Markham and Jan Leschly of Care Capital have joined the firm's board of directors. Vaxart said it will use the funding to advance its lead product, an oral vaccine for Avian influenza, through Phase I clinical trials.
posted on Thursday, March 4, 2010 (Link to more information)
Related companies:
Vaxart
Related stories:
> Vaxart Gets $3.5M
> Vaxart Raises $3.3M In Series A For Flu Vaccine
> Meissa Vaccines Finds Funding
> PaxVax Gets $62M For Vaccine Efforts
> Drip Drop Captures $2.3M More
silicontap.com Home